EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

NCT05703815 | Unknown

• 1 other identifier: Soh-Med-23-01-34
• Study Type: observational
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world. In Egypt, breast cancer represents the 2nd most diagnosed cancer among all population. But among Egyptian females it represents the 1st diagnosed cancer representing 32.4%. The main cause of death in breast cancer patients is tumor metastasis. Although only 5-10% of recently diagnosed breast cancer cases show metastasis to distant sites, but still there is a high risk for metastasis in patients with localized primary tumor following successful surgical management. Epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule. It modifies cadherin mediated cell adhesion and it induces epithelial cell migration and proliferation. Some authors elucidate that EpCAM is involved in metastasis. P53 is a known tumor suppressor gene involved in the control of cell cycle, DNA repair and apoptosis. It's one of the most mutated genes in cancer including breast cancer. Mutant p53 has a big role in tumor progression.

Conditions

Invasive Breast Cancer

Keywords

EpCAM, P53 , IDC

Outcome Measures

Primary Outcomes (1)

• Diagnosis of breast cancer

  Immunohistochemical expression of EpCAM and P53 in IDC of the breast

  two day after staining sections with Immnnohistochemical markers

Eligibility Criteria

• Age: 20 Years - 80 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

formalin-fixed and paraffin embedded tissue blocks from 40 patients with breast cancer

You may qualify if:

• \- Both incisional and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study.
• \. Complete clinical data.

You may not qualify if:

• Patients with recurrence of the primary tumor.
• Patients with a history of preoperative chemotherapy and/or radiotherapy.
• Insufficient or tiny tissue biopsies

Sponsors & Collaborators

• Sohag University: lead

MeSH Terms

Conditions

Colorectal Cancer, Hereditary Nonpolyposis, Type 8

Study Officials

• Rasha M Abdelkareem

  Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rasha M Abdelkareem, lecturer

CONTACT

01158408563; rasha_abdelkareem@med.sohag.edu.eg

Rasha M Abdelkreem, lecturer

CONTACT

01022085207; rasha_abdelkareem@med.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer

Study Record Dates

• First Submitted: January 19, 2023
• First Posted: January 30, 2023
• Study Start: January 1, 2023
• Primary Completion: March 1, 2023
• Study Completion: March 1, 2023
• Last Updated: January 31, 2023

Record last verified: 2023-01